Physician profile
Amy Tiersten
NPI 1558362566
$34,781.20
in general payments reported to CMS, 2019-2025
23 companies · $6,492 in 2025
The $6,492 reported for 2025 was more than what 77% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $6,233 · 2021: $179 · 2022: $218 · 2023: $5,137 · 2024: $5,507 · 2025: $6,492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Food and Beverage: $2,166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,970.00 |
| Food and Beverage | $2,165.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $13,342.95 | 2019-2025 | Truqap, Datroway |
| Novartis Pharmaceuticals Corporation | $8,229.11 | 2019-2025 | |
| Genentech USA, INC. | $4,504.45 | 2019-2025 | Phesgo, Itovebi |
| Athenex Pharmaceutical Division, LLC | $4,000.00 | 2020 | |
| Eisai INC. | $1,675.00 | 2019-2020 | |
| Abbvie INC. | $1,375.00 | 2020 | |
| Stemline Therapeutics INC. | $382.89 | 2024-2025 | Orserdu |
| Daiichi Sankyo INC. | $271.09 | 2023-2025 | Enhertu |
| Jazz Pharmaceuticals INC. | $191.83 | 2024 | |
| Amgen INC. | $188.07 | 2019-2022 | |
| Hologic Sales and Service, LLC | $150.00 | 2025 | Aptima |
| Astrazeneca Uk Limited | $135.00 | 2024 | |
| Glaxosmithkline, LLC. | $125.00 | 2020 | |
| Pfizer INC. | $59.79 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $49.98 | 2019-2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $44.73 | 2021-2022 | |
| Celgene Corporation | $24.46 | 2019 | |
| Puma Biotechnology, INC. | $18.86 | 2025 | |
| Ge Healthcare | $12.99 | 2022 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Tiersten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.